Prospects for the treatment of Parkinson's disease using neural grafts

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 5, 2000, Pages 889-902

  Barker, Roger A ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Neural transplants; Parkinson's disease treatment

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE;

ANIMAL; BRAIN TRANSPLANTATION; FETAL TISSUE TRANSPLANTATION; HUMAN; PARKINSON DISEASE; PHYSIOLOGY; REVIEW; SUBSTANTIA NIGRA; TRANSPLANTATION;

ANIMALS; ANTIPARKINSON AGENTS; BRAIN TISSUE TRANSPLANTATION; DOPAMINE; FETAL TISSUE TRANSPLANTATION; HUMANS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 0034231848     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.5.889     Document Type: Article

References (61)

1. STOCCHI F, NORDERA G, MARSDEN CD: Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Clin. Neitmpharmacol. (1997) 20:95-115.
2. DUNNETT SB, BJÖRKLUND A: Prospects for new restorative and neuroprotcctivc treatments in Parkinson's disease. Nature (1999) 399-32-A39. A useful review article outlining the recent advances in PD and possible new therapeutic approaches.
3. LANG AE, LOZANO AM: Parkinson's disease. N. Engl.J. Med. (1998) 339:1044-1053; 1130-1143.
4. PARKINSON'S DISEASE CONSENSUS WORKING PARTY: Guidelines for the management of Parkinson's disease. Hospital Medicine (1998) 59:469-480.
5. DRUGS & THERAPEUTICS BULLETIN: Developments in the treatment of Parkinson's disease. Drugs & Therapeutics Bulletin (1999) 37:36-40.
6. SPILLANTINI MG, SCHMIDT ML, LEE VM et al.: Alpha synuclcin in Lewy bodies. Nature (1997) 338:839-840.
7. POLYMEROPOULOS MH, LAVEDAN C, LEROY E et ah. Mutation in the alpha-synuclcin gene identified in families with Parkinson's disease. Science (1997) 276:2045-2047.
8. FEARNLEY J, LEES AJ: Parkinson's disease: Neuropa-thology. In: Movement Disorders. Neurologic principles and practice. Watts RL, Koller WC (Eds.), McGraw-Hill, New York, USA (1997):2o3-277.
9. BROTCHIE JM: Novel approaches to the symptomatic treatment of parkinsonian syndromes: alternatives and adjuncts to dopamine-rcplaccmcnt. Ctirr. Opin. Neural. (1997) 10:340-345-
10. SCHATZLHM:Neurotrophicfactors:readytogo? Trends Neurosci. (1995) 18:463-464.
11. HUGHES AJ, DANIEL SE, KILFORD L, LEES AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J. Neural. Neurosurg. Psycbiat. (1992) 55:181-184. An important study in highlighting the difficulties of diagnosing PD in life, which will thus contaminate any studies with small number of patients involving new experimental therapies.
12. HUGHES AJ, DANIEL SE, BLANKSON S, LEES AJ: A clinicopathological study of 100 cases of Parkinson's disease. Arch. Neural. (1993) 50:140-148.
13. ZETUSKY WJ, JANKOVIC J, PIROZZOLO FJ: The heterogeneity of Parkinson's disease: Clinical and prognostic implications. Neural. (1985) 35:522-526.
14. GRAHAM JM, SAGAR HJ: A data-driven approach to the study of heterogeneity in idiopathic Parkinson's disease: Identification of three distinct subtypes. Mou. Disorders (1999) 14:10-20.
15. LOZANO AM, LANG AE, HUTCHISON WD, DOSTROVSKY JO: New developments ir understanding the etiology of Parkinson's disease and in its treatment Cuir. Opin. Neurobiol. (1998) 8:783-790.
16. OBESO JA, GURIDI J, DELONG M: Surgery for Parkinson's disease. J. Neural. Neiirosurg. Psycbiat. (1997) 62:2-8.
17. KRACK P, POLLAK P, LIMOUSIN P et al.: Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. Brain (1998) 121:451-457.
18. Neural repair, transplantation and rehabilitation. Barker RA, Dunnett SB (Eds.), Psychology Press, Hove, UK (1999). A useful summary on mechanisms of CNS repair and neural transplantation in range of disorders, using a variety of approaches.
19. BARKER RA. DUNNETT SB: The biology and behaviour of intraccrebral adrenal transplants in animals and man. Rev. Neurosci. (1993) 4:113-146.
20. BARKER RA, ROSSER AE, DUNNETT SB: Preparation of cell suspensions for transplantation. In: NeuroMethods: Cell and Tissue Transplantation in the CNS. Dunnett SB, Boulton AA, Baker BB (Eds.), Humana Press, Totowa, NJ, USA (1999):195-206.
21. LINDVALL O: Neural transplantation: a hope for patients with Parkinson's disease. Netiroreport (1997) 8:iii-x.
22. FOLKERTH RD, DURSO R: Survival and proliferation of non-neural tissues, obstruction of cerebral ventricles, in a parkinsonian patient treated with fetal allografts. Neurology (1996) 46:1219-1225.
23. DEFER GL, WIDNER H, MARIE RM et al.: Core assessment program for surgical intcrvcntional therapies in Parkinson's disease (CAPSIT-PD). Mov. Disorders (1999) 14:572-584. The guidelines for studies using surgical interventions in PD, which should be adopted by all centres contemplating clinical trials with neural grafts. It replaces the original Core assessment Program for Intracerebral Transplantations (CAPIT), which was originally published in 1992 and provided the minimal requirements for a common patient evaluation protocol.
24. LINDVALL O, GUSTAVII B, ASTEDT B et al.: Fetal dopaminc-rich mcsenccphalic grafts in Parkinson's disease. Lancet (1988) ii:1483-1484.
25. MADRAZO I, LEON V, TORRES C et ah. Transplantation of fetal substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkinson's disease. N. Engl.J. Med. (1988) 318:51.
26. WIDNER H: The Lund transplant program for Parkinson's disease and patients with MPTP-induced parkinsonism. In: Cell Transplantation for Neurological disorders: Toward reconstruction of the human central nervous system. Freeman TB, Widner H (Eds.), Humana Press, Totowa, NJ. USA (1998):1-17.
27. Tliis is the first full account of all the patients transplanted in Lund University by the Swedish team.
28. BRUNDIN P: Dissection, preparation and implantation of human embryonic brain tissue. In: Neural Transplantation: A Practical Approach. Dunnett SB, Björklund A (Eds.), IRL Press, Oxford, UK (1992):139-l60.
29. LINDVALL O, REHNCRONA S, BRUNDIN P et ah Human fetal dopamine neurons grafted into the striatum in 2 patients with severe Parkinson's disease: a detailed account of methodology and a 6-month follow-up. Arch. Netirol. (1989) 46:615-631.
30. KISH SJ, SHANNAK JK, HORNYKIEWICZ O: Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: Pathophysiologic and clinical implications. N. Engl. J. Med. (1988) 318:876-881.
31. FREEMAN TB, OLANOW CW, HAUSER RA et al.: Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann. Neural. (1995) 38:379-388.
32. PICCINI P, BROOKS DJ, BJÖRKLUND A et a!.-. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient Nat. Nettrosci. (1999) 2:1137-1140. This is a convincing account of graft survival 10 years after implantation with restoration of normal dopaminergic transmission within the striatum on the grafted side. In contrast, the host dopaminergic innervation continued to decline with disease progression.
33. HAGELL P, SCHRÄG A, PICCINI P et a!.: Sequential bilateral transplantation in Parkinson's disease. Effects of a second graft. Brain (1999) 122:1121-1132.
34. WENNING GK, ODIN P, MORRISH P et al.-. Short- and long-term survival and function of unilateral intrastriatal dopamincrgic grafts in Parkinson's disease. Ann. Neural (1997) 42:95-107.
35. LINDVALL O, SAWLE G, WIDNER H et al: Evidence for long-term survival and function- of dopamincrgic grafts in progressive Parkinson's disease. Ann. Neurol. (1994) 35:172-180.
36. HAUSER RA: Fetal nigral transplantation in Parkinson's disease: the USF pilot program (12 to 24 month evaluation). In: Cell Transplantation for Neurological disorders: Toward reconstruction of the human central nervous system. Freeman TB, Widner H (Eds.), Humana Press, Totowa, NJ, USA (1998):19-30.
37. RÉMY P, SAMSON Y, HANTRAYE P et al: Clinical correlates of ["Fjfluorodopa uptake in five grafted Parkinsonian patients. Ann. Neural. (1995) 38:580-588.
38. PESCHANSKI M, DEFER G, DETHY S et al: Toward a Phase III multicenter study of fetal ventral mesencephalic transplants in patients with late-stage Parkinson's disease. In: Cell Transplantation for Neurological disorders: Toward Reconstruction of the Human Central Nenmis System. Freeman TB, Widner H (Eds.), Humana Press, Totowa, NJ, USA (1998):31-44.
39. REDMOND DE, LERANTH C, SPENCER DD et ah. Fetal neural graft survival. Lancet (1990) 336:820-822.
40. KORDOWER JH, FREEMAN TB, OLANOW CW: Neuropathology of fetal nigral grafts in patients with Parkinson's disease. Mov. Disorders (1998) 13:88-95. A summary account of the postmortem findings in patients receiving neural grafts for PD, showing that clinically beneficial grafts have large number of surviving dopaminergic neurones and fibre outgrowth.
41. OLANOW CW, KORDOWER JH, FREEMAN TH: Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Keurosct. (1996) 19:102-109.
42. SCHIELEGS, HANSSON O, LEIST M et al: Caspase inhibition reduces apoptosis and increases survival of nigral transplants. Nat. Med. (1999) 5:97-100.
43. BARKER RA, DUNNETT SB, FAWCETT JW: Neurotrophic factors and neural grafts: a growing field. Sem. Neural. (1993) 5:431-441.
44. KORDOWER JH, PALFI S, CHEN E-Y et al.: Clinicopathological findings following intravcntricular glialdcrivcd ncurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neural. (1999) 46:419-424.
45. The first postmortem study in a patient receiving an intraventricular delivery of a neurotrophic factor showing no endogenous repair of the patients dopaminergic nigrostriatal pathway.
46. OLSON L, BACKLUND EO, EBENDAL T et al.: Intraputaminal infusion of nerve growth factor to support adrenal medullary autografts in Parkinson's disease: one year follow-up of first clinical trial. Arch. Neural. (1991)48373-381.
47. FREED CR, BREEZE RE, ROSENBERG ML et at.: Transplantation of human fetal dopamine cells for Parkinson's disease. Results at 1 year. Arch. Neural. (1990) 47:505-512.
48. FREED CR, BREEZE RE, ROSENBERG NL et al.i Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. A'. Engl. J. Med. (1992) 327:1549-1555.
49. FAHN S, GREENE PE, TSAI WY et al.: Double-blind controlled trial of human embryonic dopaminergic tissue transplants in advanced Parkinson's disease: clinical outcomes. Neurology (1999) 52 (Suppl. 2):A405.
50. FREEMAN TB, SANBERG PR, NAUERT GM et al.: The influence of donor age on the survival of solid and suspension intraparenchymal human embryonic nigral grafts. Cell Transplantation (1995) 4:141-154.
51. W1DNER H, BRUNDIN P: Immunological aspects of grafting in the mammalian central nervous system: a review and speculative synthesis. Brain Research Kevieu'sWSS) 13:287-324.
52. BARKER RA: Porcine neural xenografts: What are the issues? Noi'artis Symposium Foundation 231. (In Press).
53. SCHUMACHER JM, ELLIAS SA, PALMER EP et a!.: Transplantation of embryonic porcine mescncephalic tissue in patients with Parkinson's disease. Neurology (2000) 54:1042-1050.
54. DEACON T, SCHUMACHER J, DINSMORE J et al.; Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. Nature Meet. (1997) 3:350-353.
55. A postmortem study on a patient receiving a porcine ventral mesenceplialic xenograft showing poor graft survival in terms of dopaminergic neurones.
56. PARADIS K, LANGFORD G, LONG Z et al.: Search for cross-species transmission of porcine endogenous retrovims in patients treated with living pig tissue. Science (1999) 285:1236-1241.
57. BARKER RA, KENDALL AL, WIDNER H AND THE 'NEURAL TISSUE XENOGRAFTING PROJECT': Neural tissue xenotransplantation: What is needed prior to clinical trials? Cell Transplant. 9:235-246. This paper lays out all the criteria that must be fulfilled prior to any clinical trials with porcine xenografts in PD. It sets out the minimum data that should be obtained experimentally before considering the use of this tissue in patients.
58. ARMSTRONG RJE, SVENDSEN CN: Neural stem cells: from cell biology to cell replacement. Cell Transplant. (In Press).
59. SVENDSEN CN, SMITH AG: New prospects for human stem-cell therapy in the nervous system. Trends Neiirosci. (1999) 22:357-364.
60. STUDER L, TABAR V, MCKAY RD: Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats. Nature Neiirosci. (1998) 1:290-295.
61. FRICKER J: Human neural stem cells on trial for Parkinson's disease. Mol. Med. Today (1999) 5:144.